Practical guide
Tepezza Hearing Loss Lawsuit Status in 2026
Suffering from tinnitus after Tepezza? Get the 2026 litigation updates, eligibility criteria, and settlement timelines to secure your legal claim today.
Disclaimer: This article is informational only and does not constitute legal advice. Mass tort and class action eligibility, deadlines, and settlement procedures vary by jurisdiction and individual circumstances. For specific case evaluation, consult a qualified attorney licensed in your state. Any payout ranges mentioned reflect publicly disclosed settlement administrator data and do not guarantee individual outcomes.
As of October 2026, the legal landscape surrounding Tepezza (teprotumumab) has reached a critical juncture for thousands of patients across the United States. Originally hailed as a breakthrough treatment for Thyroid Eye Disease (TED), Tepezza has become the subject of intense litigation due to its association with permanent hearing loss and tinnitus. For individuals who underwent treatment and subsequently experienced auditory impairment, the year 2026 represents a pivotal window for seeking accountability. According to the U.S. District Courts (USDC) Judicial Panel on Multidistrict Litigation (JPML), hundreds of cases have been consolidated into a single proceeding to streamline the complex discovery and trial processes.
The core of the Tepezza hearing loss lawsuit centers on allegations that the manufacturer, Horizon Therapeutics (now a subsidiary of Amgen), failed to adequately warn patients and healthcare providers about the risks of irreversible hearing damage. While the medication was approved to reduce eye bulging and double vision associated with TED, early clinical data suggested a much higher incidence of hearing-related side effects than what was initially disclosed on the product label. In 2026, the focus of the litigation has shifted from preliminary motions to the preparation for bellwether trials, which are intended to test the strengths of the arguments on both sides and potentially pave the way for a global settlement framework.
The Current State of Tepezza Litigation in 2026
As we move through 2026, the Tepezza litigation is primarily organized under Multi-District Litigation (MDL) No. 3079, centralized in the Northern District of Illinois. This consolidation allows a single federal judge to oversee the pretrial proceedings, including the exchange of evidence (discovery) and the vetting of expert witnesses. For consumers, this structure is significant because it ensures consistency in legal rulings and prevents the duplication of efforts across different jurisdictions. The USDC JPML records indicate that the number of filings has continued to grow as more patients become aware of the link between their infusions and their subsequent hearing difficulties.
The year 2026 is particularly noteworthy because the court has entered the advanced stages of the “bellwether” process. These representative cases are selected to go to trial first, serving as a barometer for how future juries might react to the evidence presented. The outcomes of these trials often dictate the momentum of settlement negotiations. If the plaintiffs secure significant verdicts, it may encourage the manufacturer to establish a settlement fund to resolve the thousands of remaining claims. Conversely, if the defense prevails, the litigation may continue for several more years. Prudent observers note that while no universal settlement has been reached as of late 2026, the pressure on the defendant is mounting as more clinical studies corroborate the high risk of ototoxicity associated with teprotumumab.
For those considering a claim in 2026, it is essential to understand that these lawsuits are not part of a traditional class action where everyone receives an identical, often nominal, payout. Instead, the Tepezza MDL consists of individual personal injury lawsuits that have been grouped for efficiency. This means that any potential compensation would be based on the specific damages suffered by the individual, such as the severity of their hearing loss, the impact on their quality of life, and their documented medical expenses. Consulting a qualified attorney through the American Bar Association (ABA) lawyer referral service can help individuals navigate these distinctions.
Documented Side Effects and the FDA Label Evolution
The medical community’s understanding of Tepezza’s side effects has evolved significantly since its initial release. Teprotumumab works by inhibiting the insulin-like growth factor-1 receptor (IGF-1R), which is overexpressed in the orbital tissues of TED patients. However, IGF-1R also plays a vital role in the health and maintenance of the inner ear’s hair cells. When this receptor is blocked, it can lead to various forms of auditory dysfunction. Patients have reported a range of symptoms, including sensorineural hearing loss, which involves damage to the inner ear or the nerve pathways from the inner ear to the brain.
In addition to standard hearing loss, many claimants in the 2026 litigation report suffering from tinnitus (a persistent ringing or buzzing in the ears) and autophony. Autophony is a distressing condition where a person perceives their own voice or breathing as abnormally loud or echoing. These symptoms often do not resolve after the cessation of Tepezza treatment, leading to the “permanent” designation that forms the basis of many legal claims. While the FDA required a label update in 2023 to include more explicit warnings about the risk of permanent hearing loss, many plaintiffs argue that this warning came far too late for those treated during the first few years of the drug’s availability.
Current medical literature cited in 2026 filings suggests that the incidence of hearing issues may be as high as 65% among treated patients, a stark contrast to the initial 10% reported in early clinical trials. This discrepancy is a cornerstone of the “failure to warn” legal theory. Attorneys representing injured parties are focusing on internal documents to determine when the manufacturer became aware of these higher risks and why the information was not disseminated to the public sooner. For patients, the diagnosis of these conditions by an audiologist or otolaryngologist is a critical piece of evidence required to sustain a legal claim in 2026.
Determining Eligibility for a Tepezza Hearing Loss Claim
Eligibility for filing a Tepezza hearing loss lawsuit in 2026 depends on several specific criteria that must be verified through medical records and legal review. Generally, a potential claimant must have received one or more infusions of Tepezza for the treatment of Thyroid Eye Disease. The timing of the treatment is less important than the subsequent development of hearing-related issues, provided the claim is filed within the relevant legal deadlines. Because the litigation is ongoing, new claimants are still being accepted into the MDL framework, provided they meet the evidentiary thresholds.
The primary eligibility requirements in 2026 typically include:
1. **Proof of Tepezza Administration:** Documentation showing the dates and dosages of teprotumumab infusions.
2. **Diagnosis of Hearing Impairment:** Medical records from a specialist (such as an ENT or audiologist) confirming hearing loss, tinnitus, or other auditory issues that began during or after treatment.
3. **No Prior Hearing Issues:** While not always a disqualifier, cases are strongest when the claimant had no significant history of hearing loss before starting Tepezza.
4. **Adherence to Timelines:** The claim must be filed before the expiration of the statute of limitations, which varies by state.
It is important to note that eligibility is ultimately determined by a qualified attorney after a thorough review of the case facts. Many law firms in 2026 offer free consultations to help patients determine if their specific situation aligns with the current litigation strategy. Furthermore, the severity of the hearing loss often dictates the viability of the case; those with permanent, bilateral hearing loss requiring hearing aids or cochlear implants are generally prioritized in the litigation process due to the high level of damages involved.
Statutes of Limitations and Legal Deadlines in 2026
One of the most critical factors for any potential plaintiff in 2026 is the statute of limitations. This is a legal deadline by which a lawsuit must be filed, or the right to sue is forever lost. Because Tepezza claims are personal injury actions, the deadlines are governed by state law, and they can vary significantly from one jurisdiction to another. For example, under California Code of Civil Procedure § 335.1, the statute of limitations for personal injury is generally two years from the date of the injury or the date the injury was discovered. In contrast, Florida Statutes § 95.11 provides a different timeframe, which was recently modified in 2023, affecting how claims are calculated in 2026.
The “discovery rule” is often a central point of contention in Tepezza cases. This rule suggests that the clock on the statute of limitations does not start ticking until the patient reasonably should have known that their hearing loss was caused by the medication. Since many patients were not warned about the permanent nature of the side effects, they may not have connected their hearing loss to Tepezza until much later. However, as the risks have become more widely publicized by 2026, defendants are increasingly arguing that patients should have been aware of the link earlier, potentially barring late-filed claims. This makes it imperative for anyone experiencing symptoms to seek legal counsel immediately to preserve their rights.
| Litigation Phase | Status as of 2026 | Impact on Claimants |
|---|---|---|
| MDL Consolidation | Active (MDL No. 3079) | Centralized discovery and pretrial motions. |
| Bellwether Trials | In Progress / Scheduled | Sets the “value” and trajectory for settlements. |
| Discovery Phase | Advanced / Expert Phase | Exchange of internal company documents and expert testimony. |
| Settlement Negotiations | Ongoing / Confidential | Potential for global resolution based on trial outcomes. |
Potential Settlement Values and Compensation Factors
As of 2026, there is no fixed “average” settlement for a Tepezza hearing loss claim, as no global settlement agreement has been finalized. However, legal experts often look at similar pharmaceutical torts involving permanent sensory loss to estimate potential ranges. Compensation in these cases is designed to cover both economic and non-economic damages. Economic damages include the cost of medical care, hearing aids, speech therapy, and any loss of earning capacity if the hearing loss affects the individual’s ability to work. Non-economic damages cover “pain and suffering,” loss of enjoyment of life, and the emotional distress associated with a permanent disability.
The potential value of a Tepezza settlement in 2026 depends on several case-specific factors:
– **Severity of Hearing Loss:** Complete deafness or profound loss typically commands higher compensation than mild tinnitus.
– **Age of the Plaintiff:** Younger individuals may receive higher awards due to the longer duration they will live with the disability.
– **Unilateral vs. Bilateral:** Damage to both ears is generally valued higher than damage to a single ear.
– **Impact on Employment:** If the claimant’s profession relies heavily on hearing (e.g., a musician or teacher), the damages may increase.
– **Jurisdiction:** Some states have caps on non-economic damages which can limit the total recovery.
Based on historical data from other ototoxicity litigations, settlement ranges can vary widely. Some estimates suggest that moderate cases could settle in the range of $50,000 to $150,000, while severe, permanent hearing loss cases involving younger plaintiffs could potentially reach $300,000 to $500,000 or more. These figures are purely speculative and depend entirely on the outcomes of the 2026 bellwether trials and the willingness of the defendant to negotiate. It is vital to remember that these ranges are not guarantees of any specific outcome.
Key Settlement Figures and Metrics for 2026
- Projected Bellwether Trial Dates: Multiple trials are scheduled throughout late 2026 to determine liability.
- Estimated Number of Filings: Over 1,500 cases are currently pending in the federal MDL as of the most recent 2026 report.
- Common Damage Categories: Medical monitoring, cost of future hearing aid replacements (every 5-7 years), and loss of consortium.
- Attorney Fee Structure: Most cases in 2026 are handled on a contingency fee basis, typically ranging from 33% to 40% of the final recovery.
- Discovery Milestones: Millions of pages of internal corporate documents have been reviewed by plaintiff steering committees as of 2026.
Frequently Asked Questions (FAQ)
Is there a class action lawsuit for Tepezza hearing loss?
As of 2026, there is no traditional class action for Tepezza hearing loss that results in a single lump-sum payment for all members. Instead, the cases are consolidated into a Multi-District Litigation (MDL). This allows for individual lawsuits to be handled efficiently while ensuring that each plaintiff’s specific medical history and damages are considered separately. This structure is generally more favorable for personal injury victims than a class action.
What is the current status of Tepezza hearing loss litigation?
The litigation is currently in the advanced pretrial phase within MDL No. 3079 in the Northern District of Illinois. In 2026, the court is focusing on bellwether trials and expert witness testimony (Daubert hearings). These steps are necessary to determine which scientific evidence will be allowed at trial and to establish the potential settlement value of the thousands of pending claims.
Who is eligible to file a Tepezza hearing loss lawsuit?
Eligibility generally requires that you received Tepezza infusions for Thyroid Eye Disease and subsequently developed documented hearing loss, tinnitus, or other auditory damage. In 2026, attorneys are looking for clear medical evidence linking the onset of symptoms to the timing of the medication. A review of your medical records by a legal professional is the only way to confirm eligibility.
What are the potential side effects of Tepezza?
While the most serious side effects being litigated in 2026 are permanent hearing loss and tinnitus, Tepezza is also associated with muscle spasms, nausea, diarrhea, fatigue, and changes in blood sugar levels. The legal focus remains on the auditory issues because they were allegedly not properly disclosed as potentially permanent risks on the original drug label.
How long do I have to file a Tepezza hearing loss claim?
The time limit, or statute of limitations, depends on the laws of the state where you live or where the treatment occurred. In 2026, many of these deadlines are approaching. Because the “discovery rule” can be complex to apply, it is vital to contact a lawyer as soon as you suspect a link between your hearing loss and Tepezza to ensure your claim is filed before the legal window closes.
Conclusion and Next Steps for Consumers
The Tepezza hearing loss litigation of 2026 represents a major effort to hold pharmaceutical manufacturers accountable for patient safety. For those suffering from the life-altering effects of hearing impairment after TED treatment, the legal system offers a pathway to recover compensation for medical bills and the loss of quality of life. However, the window for action is narrowing as statutes of limitations expire and the MDL moves toward final trial phases. Understanding your rights and the current status of the litigation is the first step toward achieving a resolution.
If you or a loved one has experienced hearing changes following Tepezza infusions, the most prudent course of action in 2026 is to gather your medical records and seek a professional legal evaluation. You can find qualified legal assistance through the American Bar Association’s lawyer referral service or by contacting your local state bar association. These organizations can connect you with attorneys who specialize in pharmaceutical litigation and who can provide guidance tailored to your specific jurisdiction and medical history. As the 2026 bellwether trials proceed, staying informed will be essential for any claimant seeking to navigate this complex legal journey.
Need to find a qualified attorney? The ABA Lawyer Referral Service Directory provides state-by-state directories of certified lawyer referral services. State bar associations also maintain attorney verification tools. Avoid claims aggregators and choose attorneys with documented mass tort experience.
This article is informational only and does not constitute legal advice. Statute of limitations, eligibility, and settlement amounts vary by case specifics and jurisdiction. Last updated: June 2026.
